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Abstract
Background: Randomized controlled trials are considered the gold standard to evaluate causal associations,
whereas assessing causality in observational studies is challenging.
Methods: We applied Hill’s Criteria, counterfactual reasoning, and causal diagrams to evaluate a potentially causal
relationship between an exposure and outcome in three published observational studies: a) one burden of disease
cohort study to determine the association between type 2 diabetes and herpes zoster, b) one post-authorization
safety cohort study to assess the effect of AS04-HPV-16/18 vaccine on the risk of autoimmune diseases, and c) one
matched case-control study to evaluate the effectiveness of a rotavirus vaccine in preventing hospitalization for
rotavirus gastroenteritis.
Results: Among the 9 Hill’s criteria, 8 (Strength, Consistency, Specificity, Temporality, Plausibility, Coherence,
Analogy, Experiment) were considered as met for study c, 3 (Temporality, Plausibility, Coherence) for study a, and 2
(Temporary, Plausibility) for study b. For counterfactual reasoning criteria, exchangeability, the most critical
assumption, could not be tested. Using these tools, we concluded that causality was very unlikely in study b,
unlikely in study a, and very likely in study c. Directed acyclic graphs provided complementary visual structures that
identified confounding bias and helped determine the most accurate design and analysis to assess causality.
Conclusions: Based on our assessment we found causal Hill’s criteria and counterfactual thinking valuable in
determining some level of certainty about causality in observational studies. Application of causal inference
frameworks should be considered in designing and interpreting observational studies.
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Background
Since the beginning of this century, an unprecedented
amount of scientific research has been conducted on
causal inference, the process of assessing causality be-
tween exposures and outcomes. Many epidemiological
studies are observational in their design, and unlike
randomized controlled trials (RCT) where similarity of
groups can be experimentally attained, comparability of
groups can be difficult or even impossible to demon-
strate. This renders causal inference in these cases chal-
lenging and conditional on unverifiable assumptions.
To infer causality from association, Sir Austin Bradford
Hill synthesized what he called “aspects of association” [1],
consisting of 9 distinct criteria that can be used separately
or in combination to gather evidence on causal inference.
These criteria are known as ‘Hill’s criteria’ and have been
extensively used among epidemiologists ever since. More
recently, other elaborate frameworks for causal inference
have been developed [2–4], stemming from graph theory
and counterfactual theories of causation. The counterfac-
tual framework published by Rubin, 1974 [5], led to the
definition of three general conditions needed to draw
causal inference; exchangeability, consistency and positiv-
ity. Causal Diagrams in the form of Directed Acyclic
Graphs (DAGs), summarize the assumed relationships be-
tween all variables that are relevant to the causal analysis
and can be used to detect confounding and selection bias,
and to develop insights on how to adjust for them in data
analysis or in the study design. We assessed the applicabil-
ity and limitations of these approaches in drawing causal
inference in observational studies in the context of vaccine
research.
Vaccine studies have some particularities that may
influence causal analyses. For example, vaccination not
only protects the vaccinee but can also reduce the trans-
mission of contagious disease in the unvaccinated popu-
lation (herd immunity). RCTs measure the effect of the
vaccine at the individual subject level to demonstrate the
vaccine efficacy for approval by health authorities,
whereas epidemiological studies are needed to measure
the effect of vaccination (effectiveness and impact) at the
population level [6]. We assessed how classical and more
recent causal inference methods, namely Hill’s criteria,
counterfactual framework, and causal diagrams, are
applicable in vaccine research, using examples from
epidemiological studies.
Methods
We applied Hill’s Criteria, counterfactual reasoning, and
causal diagrams to three published studies conducted by
GSK: one burden of vaccine target disease (BoD) study,
one post-authorization safety study (PASS), and one vac-
cine effectiveness (VE) study. Based on the published re-
sults, for each study Hill’s criteria and counterfactual
reasoning were rigorously discussed and assessed by the
authors in several meetings until a consensus was
reached. No additional analysis was performed during
this exercise. Causal diagrams were drawn to depict the
exposure, outcome and other factors for each study
using standard symbols [7]. The selection and matching
factors were symbolized as factors associated with S = 1
[Selection]. Other covariates controlled in the analysis
were depicted as associated with both exposure and out-
come (Fig. 1).
Description of studies
The objectives, design and characteristics (estimand,
sample size, statistical model, and the main results) of
the three selected studies are summarized in Fig. 1.
BoD study
This retrospective matched cohort study used the Inte-
grated Health Care Information Services database in the
United States (US) to assess whether diabetes mellitus
(DM) is a risk factor for herpes zoster (HZ) [8]. Four co-
horts were defined: a type I diabetes mellitus cohort
(DM1), a type II diabetes mellitus cohort (DM2) and
two comparative matched cohorts of non-diabetics.
Therefore, the target estimand was the average exposure
effect in the exposed subjects. Cox proportional-hazards
regression analysis was applied to compare the risk of
HZ among diabetics vs. non-diabetics, controlling for
other factors that might be associated with the risk of
HZ, such as age, sex, cardiac and chronic pulmonary
diseases. As shown in the causal diagram (Fig. 1), these
factors are also associated with the outcome (HZ) via
two mediators, waning immunity and varicella zoster
virus (VZV) reactivation. Additionally, several conditions
possibly associated with both DM2 and waning immun-
ity were excluded by design (S = 1 refers to selection
criteria).
The study showed that DM2 was associated with an
increased risk of developing HZ, with age acting as an
effect modifier. The Hazard Ratio (HR) associated with
DM2 was 3.12 (95% confidence interval [CI]: 2.77–3.52)
in subjects aged ≥65 years. Cardiac disease and chronic
pulmonary disease were also associated with an in-
creased risk (HR 1.92, 95% CI 1.73–2.13 and 1.52, 95%
CI 1.38–1.67, respectively) and modified the association
between DM2 and the risk of HZ.
PASS: cohort study
This retrospective cohort study used the Clinical Practice
Research Datalink GOLD database [11], containing linked
anonymized longitudinal medical records from primary
care practices in the United Kingdom, to evaluate the risk
of new onset of autoimmune disease (AD) in women aged
9–25 years after administration of the human
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papillomavirus vaccine, AS04-HPV-16/18 (Cervarix, GSK)
[9]. The two co-primary objectives assessed whether AS04-
HPV-16/18 vaccination was associated with an increased
risk of neuro-inflammatory/ophthalmic AD or other ADs
within 12months of receiving the first dose. The study in-
cluded an exposed cohort vaccinated with AS04-HPV-16/
18 and an historical unexposed cohort of approximately 65,
000 subjects each. The cohorts were frequency-matched for
age and practice region identifier. The target estimand was
the treatment effect in vaccinated subjects.
The cohorts were compared using a Poisson regression
adjusted for potential confounders, “use of health care
resources” and “other vaccinations” as depicted in the
causal diagram (Fig. 1).
This study did not show evidence of an increased risk of
the two co-primary endpoints after vaccination. Specifically,
no confirmed cases of neuro-inflammatory/ophthalmic AD
were reported in the exposed cohort. For other ADs, the ad-
justed Incidence Rate Ratio (IRR) for the vaccinated versus
the unvaccinated cohort was 1.41 (95% CI: 0.86–2.31).
VE study
This prospective, hospital-based, multicenter, matched
case-control study assessed the effectiveness of the
oral live-attenuated human rotavirus vaccine (HRV;
Rotarix, GSK) in preventing hospital admissions due to
polymerase chain reaction-confirmed rotavirus gastro-
enteritis among young children in Belgium [10]. The study
included 215 children hospitalized with rotavirus gastro-
enteritis and 276 age and hospital-matched controls. The
target estimand was defined as the average direct treat-
ment effect in subjects eligible for vaccination. VE was es-
timated using a conditional logistic regression model
controlling for factors (maternal education, household
size, sex, etc.) potentially associated with vaccination and
rotavirus disease as shown in the causal diagram (Fig. 1).
VE of two doses of HRV was 90% (95% CI: 81–95), and
VE of at least one dose was 91% (95% CI: 82–95). VE esti-
mates adjusted for potential confounders were in a similar
range.
Hill’s criteria
For each study, we considered each of the 9 criteria:
strength, consistency, specificity, temporality, biological
gradient, plausibility, coherence, experiment and analogy.
A detailed description of the Hill’s criteria is provided in
the Additional file 1.
Fig. 1 Description of the analyzed studies and causal diagrams. AD: autoimmune disease, IRR: incidence rate ratio, DAG: Directed Acyclic Graph,
CI: confidence interval, CMI, cell-mediated immunity, Ctrl: control, DM1/DM2: type 1/type 2 diabetes mellitus, COPD: chronic obstructive
pulmonary disease, GE: gastroenteritis, HPV: human papillomavirus, HR: hazard ratio, HZ: herpes zoster, RV: rotavirus, VE: vaccine effectiveness, VZV:
varicella zoster virus. Study 1 [8]. DAG: The causal association between DM2 and the risk of HZ was controlled for other factors that might be
associated with risk, such as age and underlying cardiac disease and COPD. The square around S = 1 indicates that the analysis is conditional on
having been selected into the study. Individuals with renal disease, hepatic disease, metabolic syndrome, history of HZ, or with
immunocompromising conditions were excluded from enrolment. The exposure and other factors are associated with the outcome (HZ) via two
mediators; waning CMI and VZV reactivation. Study 2 [9]. DAG: S = 1 refers to the selection criteria applied during the study. The square around
S = 1 indicates that the analysis is conditional on having been selected into the matched cohorts, age and practice region being the matching
factors. The analysis was adjusted for the potential confounders “use of health care resources” and “other vaccinations”. Study 3 [10]. DAG: The
square around S = 1 indicates that the analysis is conditional on having been selected into the case-control study. Controls were matched to
cases for age and hospital and subjects with previous nosocomial GE or contraindications to RV vaccination were excluded. The analysis was
controlled for potential confounders (maternal education, household size, sex, etc.)
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Counterfactual reasoning
We assessed the applicability of three components of
counterfactual reasoning, namely exchangeability,
positivity and consistency, briefly described below (see
Additional file 2 for a more detailed description of
these criteria).
Exchangeability means that the risk of an outcome in
one group (e.g., exposed) would have been the same as
the risk of outcome in the other group (e.g., unexposed)
of individuals with the same adjustment characteristics,
had the individuals in both groups received the same
treatment; either the treatment given to those in the
exposed group or the treatment given to those in the un-
exposed group. In randomized controlled trials exchange-
ability is assumed by design. In observational studies only
conditional exchangeability might be reached by control-
ling for covariates.
Positivity states that no individual, based on his/her
adjustment characteristics, is prevented from being
either exposed or unexposed. Positivity is required when
exposure groups are to be compared: that is, to assess
the effect of a treatment on an outcome, individuals are
typically assigned to a treatment group or to a control
group so that the effect in the two groups can be
compared and an effect estimate can be computed. If all
individuals in a study (or a subgroup of individuals with
the same adjustment characteristics) were assigned to
the same group obtaining an effect estimate would not
be possible without invoking untestable modelling
assumptions.
The concept of consistency is related to the counter-
factual notion of setting the exposure status to ‘exposed’
or ‘unexposed’ by some intervention. The consistency
assumption states that the obtained conclusions are only
relevant for interventions that are ‘non-invasive’ in the
sense of doing nothing more than setting the exposure
to a particular level. The intervention should define the
exposure status and nothing else. The intervention that
sets the exposure status to ‘exposed’ should thus not
change the outcome of the exposed individuals, if
applied to them, and likewise for the unexposed.
Results
The applicability of the three major components of causal
inference are described below and in Table 1 and in Fig. 1.
BoD study
Hill’s criteria
Overall, the association between DM2 and HZ was not
considered to be strong because it was only observed in
subjects aged ≥65 years. Consistency was not met be-
cause several epidemiological studies investigating
whether diabetes is a risk factor for HZ have yielded
contradictory conclusions, with some studies suggesting
that diabetes is a risk factor for HZ [12, 13], and others
did not show a statistically significant association [14].
The specificity criterion was not met because there are
multiple possible causes of decreased immunity that can
reactivate latent VZV leading to the manifestation of HZ
[15]. Temporality was met by design because the out-
come was incident cases of HZ after a diagnosis of dia-
betes. The biological gradient was not assessed because
of the absence of evaluation of a dose-response relation-
ship between DM2 and HZ. The criterion of plausibility
was met because there is scientific evidence showing sig-
nificantly lower levels of cell-mediated immunity to VZV
among patients with diabetes mellitus compared to
healthy individuals, suggesting that the increased risk of
HZ among diabetics may be related to decreased levels
of VZV-specific immunity [15]. Similarly, coherence can
also be considered as met because of no conflict with
the current knowledge about the natural history of HZ
[16]. The experimental criterion was not met because
the exposure could not have been induced experimen-
tally in subjects and has therefore never been studied
under this study design. The analogy criterion cannot be
assessed because there was no other similar exposure.
Counterfactual reasoning
Exchangeability was likely not met because there was
clearly a difference between diabetic and non-diabetic
subjects in terms of other factors such as age and other
confounders. Conditional exchangeability was consid-
ered plausible after adjustment for these confounding
factors, but cannot be guaranteed.
Positivity can be assumed because there are both dia-
betic and non-diabetic subjects in all levels of covariates
included in the model.
The consistency assumption is difficult to evaluate be-
cause the exposure is not an intervention, but rather a
comorbidity not caused by a well-defined intervention.
PASS: cohort study
Hill’s criteria
The association between vaccine exposure and ADs was
not considered to be strong because of the absence of
confirmed cases of neuroinflammatory/ophthalmic AD
and the IRR lower than 1.5 (and non-statistically signifi-
cant) for the other ADs. Consistency was not met because
five other studies investigating associations between HPV
vaccine exposure (AS04-HPV-16/18) and ADs found no
evidence of an association [17–21]. Since there are numer-
ous possible causes of ADs it would not be appropriate to
conclude that there was specificity. Temporality was met
because vaccine administration occurred before the out-
come. In terms of biological gradient, the assessment was
not feasible as no analyses were conducted that compared
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the effect of different doses of vaccine on the risk of the
outcomes of interest. The plausibility criterion was met as
there are known biological mechanisms that could link ex-
posure to vaccine, especially those containing adjuvants,
with neuroinflammatory/ophthalmic ADs or other ADs
[22]. In addition, as existing scientific knowledge does not
support an association between exposure to AS04-
HPV-16/18 and ADs, it is reasonable to postulate that
coherence was not met. The experiment condition
was not met because RCTs showed no differences in
the proportion and frequency of ADs between vaccine
and control groups [23]. The analogy criterion was
not met because no evidence of an association was
found for another HPV vaccine [24].
Counterfactual reasoning
The subjects in the exposed group and unexposed fe-
male group were frequency matched for age and practice
region. In addition, the study collected data on other
variables such as previous vaccinations and use of health
care resources. Matching and controlling for possible
confounders supported conditional exchangeability.
However, it is likely that the presence of other measured
and unmeasured confounders potentially associated
with the exposure and the outcome within the sub-
cohorts created by matching invalidates conditional
exchangeability. Exchangeability was also violated be-
cause the exposed and unexposed cohorts were not
concurrent.
Although the unexposed female cohort was a historical
cohort enrolled before introduction of vaccination, posi-
tivity is not violated because there was no adjustment
for calendar year. Such adjustment would make
exchangeability more plausible but would induce a
violation of positivity because there are no exposed and
unexposed individuals in the same calendar year.




The association between HRV vaccination and preven-
tion of hospital admission for rotavirus gastroenteritis
was strong, with an adjusted Odds Ratio of 0.10 (95%
CI: 0.05–0.21). Consistency holds because VE has been
reported in many other studies in different countries
[25]. Specificity criterion can be considered as met be-
cause rotavirus vaccines are effective at protecting
Table 1 Assessment of applicability of causal inference concepts to vaccine studies
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claim database. Cox Proportional hazards
regression
Analysis adjusted for age was applied to
estimate the HR of developing HZ,
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• Type II diabetes in subjects
≥65 years HR 3.12; 95% CI
2.77–3.52
• Type II diabetes in subjects
40–64 years HR 1.51; 95% CI
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• Cardiac disease HR 1.92;
95% CI 1.73–2.13
• Chronic pulmonary disease






















Retrospective cohort study to assess
the risk of autoimmune diseases in
vaccinated and unvaccinated
individuals (frequency matched for
age and practice region) using a
Poisson regression model
• IRR for “other autoimmune
diseases” in the vaccinated
and unvaccinated cohorts






















October 2006 and aged
at least 14 weeks
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• Unadjusted VE for two doses
90% (95% CI: 81–95).
• Unadjusted VE of at least














AS04-HPV-16/18 vaccine, Cervarix, GSK; CI Confidence Interval, HZ Herpes zoster, HR Hazard ratio, HRV Oral human live-attenuated rotavirus vaccine, IRR
Incidence rate ratio, OR Odds ratio, VE Vaccine effectiveness, Str Strength, Cons Consistency, Spe Specificity, Temp Temporality, Biogr Biological Gradient,
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against rotavirus infection, which is the specific cause of
rotavirus gastroenteritis. Temporality criterion is also
clearly met since the vaccination status of cases and
controls is derived considering only vaccine doses
administered at least 14 days before the onset date of
gastroenteritis. Since the viral titer in the vaccine is
defined, the biological gradient criterion could not be
assessed and it is therefore unknown. The biological
plausibility of the hypothesis of the causal association
between vaccination and disease prevention is supported
by the immunological principle that vaccination prevents
infections by pathogens, either viruses, bacteria or para-
sites by eliciting a specific immune response. The coher-
ence of the association is met given that the hypothetical
cause-and-effect interpretation does not conflict with
the natural history and biology of rotavirus gastroenter-
itis. The two globally available rotavirus vaccines (HRV
and human-bovine rotavirus vaccine) were both shown
to be highly efficacious for the prevention of rotavirus
gastroenteritis [26]. In agreement with this, the World
Health Organization recommends the inclusion of the
rotavirus vaccines into all national immunization pro-
grams since 2009 [27]. The findings of this study were in
line with results of RCT [26, 28], and of ecological stud-
ies reporting reductions in the number of admissions at-
tributable to rotavirus after introduction of vaccination
[29, 30]. The experiment criterion can therefore be
considered as met. Analogy is supported by similar esti-
mates of VE of the human-bovine reassortant rotavirus
vaccine observed in case-control studies undertaken in
the US [31, 32].
Counterfactual reasoning
Controls and cases were matched by date of birth and
hospital minimizing the confounding bias by these
factors. However, there were differences in some demo-
graphic and socioeconomic variables between cases and
controls which potentially affect the VE estimate. To
control some of these, multivariable analyses were
performed, but estimates of adjusted VE accounting for
those differences were not significantly different to those
obtained in the primary unadjusted analysis.
After taking into account the variables in the analyses
as mentioned above, we expect that the set of those co-
variates are sufficient to achieve conditional exchangeability.
In this study, the conditions of positivity and
consistency are met because of presence of vaccinated
and unvaccinated in all levels of the covariates in the
model, and well-defined vaccination.
Discussion
We assessed the applicability of Hill’s criteria, counter-
factual reasoning to investigate the plausibility of causal-
ity in three observational vaccine studies. In addition, we
described the relationship between exposure, outcome
and other factors using causal diagrams. Based on these
assessments, none of the studies allowed us to formally
demonstrate causality. Nevertheless, we did conclude
that a causal association in the VE study was very likely,
based on satisfying 8 out of 9 Hill’s criteria and demon-
stration of some degree of exchangeability attained due
to controlling for known confounders.
For the BoD study, we concluded that a causal associ-
ation between DM2 and HZ was unlikely. Three out of 9
Hill’s criteria were met: these were temporality, a critical
criterion for which the exposure precedes the outcome,
plausibility and coherence. However, although the
consistency criterion was considered as not met, several
studies showed an association between DM2 and HZ
risk. Similarly, although the strength criterion was re-
ported as not met, an association was found for individ-
uals in subjects aged ≥65 years. Regarding counterfactual
reasoning, while positivity could hold, consistency was
not met because DM is not related to any intervention.
Lastly, exchangeability was unlikely to hold because of
differences in the demographic features of the different
groups.
For the PASS cohort study, a causal association be-
tween HPV vaccination and AD was very unlikely.
Only two Hill’s criteria were met (temporality and
plausibility). As for the consistency criterion - con-
sidered as not met-, it is worth mentioning that, in
contrast to the BoD study, an association between
HPV vaccination and the risk of AD has not been
observed in any other studies. In terms of counter-
factual reasoning, vaccination met the consistency
assumption. Positivity was met because there was no
adjustment for calendar year, but this in turn makes
exchangeability unlikely. To mitigate the potential ef-
fect of different calendar years for the two female co-
horts, the authors of the study included male cohorts
to confirm that no adjustment for calendar year was
needed. This adds support to a causal interpretation,
but only under the unverifiable assumption that what
is observed in male cohorts is applicable to the fe-
male cohort.
Hill’s criteria [33–37] and causal diagrams [38, 39]
have been used previously in the design and interpret-
ation of observational studies, whereas evaluation of the
assumptions referred to as identifiability conditions by
Hernan and Robins [2] in the counterfactual framework
is often done indirectly in the discussion on confounding
as part of the study limitations in observational studies.
Interestingly counterfactual reasoning introduced the
main assumption of exchangeability which was not
reflected in Hill’s criteria. The originality of our ap-
proach is that we combined all three components and
found flaws in all three methods in their applicability to
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real-life examples of observational studies in the context
of vaccine research.
At the time of Hill’s publication 50 years ago, his
criteria were not meant to be used be used as a rigid
checklist of evidence for causation. However, they have
often been used as such. Moreover, their interpretation
has changed over time as a result of major advance-
ments in several scientific disciplines, analytical tools
and access to big data [40]. As a consequence, some au-
thors have called for revisions to Hill’s criteria [41, 42].
Several criteria are subject to interpretation, for instance
the “experiment” criterion, or are difficult to differentiate
from each other, such as “plausibility” and “coherence”
[43, 44]. In addition, not all Hill’s criteria are applicable
or quantifiable for each study type. For example, the
“biological gradient” is usually not assessable in vaccine
studies because the vaccine dose is fixed. Also, the
criterion “experiment: removal of the exposure” is rarely
applicable in observational vaccine studies. Some
researchers have recommended an evaluation of
confounding factors in addition to Hill’s criteria [45]. A
good understanding of what factors cause confounding
or selection bias can be difficult in complex (possibly
longitudinal) designs. Therefore, causal diagrams can be
helpful to gain insight via visual depictions of the rela-
tionships between factors, along with graphical tools to
assess bias. In addition, counterfactual reasoning pro-
vides a formal framework for integrating this notion of
confounding in the empirical assessment of causality.
With respect to counterfactual criteria, exchangeability
is plausibly attained in intention-to-treat analysis of ran-
domized controlled trials, but generally untestable in ob-
servational studies. However, some designs can add
support to exchangeability in observational studies, such
as self-controlled case-series where the subject is his/her
own control. Positivity criteria are met within observa-
tional study designs where, within each subgroup de-
fined by the adjustment factors, there is a positive
probability of observing exposed as well as unexposed
subjects. Consistency is usually met when exposure is a
well-defined intervention such as vaccination. However,
in many observational studies, exposure is not an inter-
vention but a condition, such as body mass index, or as
in our example, DM2. Since these exposures have no
immediate connection to a well-defined intervention,
consistency as defined in counterfactual reasoning is not
applicable. The implication is that even if the effect in-
ferred from such study was causal, caution is needed
when interpreting such an effect (e.g. the effect of dia-
betes) as there is no clearly defined strategy that would
e.g. cause or prevent diabetes. Moreover, subjects ex-
posed (or unexposed) could be extracted from large da-
tabases with coded data, as was done in our BoD study
where DM was defined using International Classification
of Diseases (ICD) codes. A systematic review of case def-
initions for diabetes using ICD-9 and ICD-10 codes
showed that coding variations and institutional practices
for medical record data extraction could significantly
alter the performance of different case definitions used
in observational studies [46]. In addition to exchange-
ability, positivity and consistency, several authors recom-
mend other conditions. Rubin’s Stable Unit-Treatment-
Value Assumption (SUTVA) includes the assumption of
no interference [47]. In the VE study, the validity of this
assumption could be in doubt because the unvaccinated
subjects can benefit from an indirect effect of vaccin-
ation via herd immunity. As a consequence, the esti-
mand of that study was the direct VE and not the total
VE [6].
We used causal diagrams to describe the design of
studies, including all known confounders that were con-
sidered for adjustment. These diagrams visualize the as-
sumptions made; unknown confounders and known but
unmeasurable confounders were therefore not depicted.
In observational studies, both exposure and outcome
may be measured with error. Since no measurement
error corrections could be made, measurement error
was not incorporated in our causal diagrams.
Several publications have described the basic principles
and recommendations for drawing causal diagrams [48].
However, there is still a lack of agreement in how to de-
pict some observational study designs, such as matched
case-control designs [49, 50]. Despite some proposals to
depict effect modifiers in causal diagrams [51, 52], the fact
that effect modification is scale-dependent implies that ef-
fect modifiers cannot be successfully incorporated into
causal diagrams, which are designed to be model-free. In
spite of these limitations, causal diagrams are a useful tool
for identifying variables that should be measured and con-
trolled for at study design [48, 53], and for interpreting
the results of analysis [39].
In the three selected studies, we assessed the causality
between a single exposure and a disease: DM2 and HZ
risk, HRV vaccination and hospitalization for rotavirus
gastroenteritis, and AS04-HPV-16/18 vaccination and
AD. In this context, it is worth pointing out that the eti-
ology of most diseases is multi-factorial. For instance,
decreased levels of VZV-specific immunity are known to
lead to the reactivation of the latent VZV that subse-
quently results in the clinical manifestation of HZ [8].
However, there are numerous causes of waning immunity
including advancing age, comorbidities, immunosuppres-
sive treatments, etc. Thus, even in the case of a well-
defined medical condition and biological cause, a set of
complex contributing mechanisms and interactions can
occur. In contrast, the PASS study included a composite
endpoint (19 different diseases were defined) and the eti-
ology of many ADs is only partially elucidated. Moreover,
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many or most ADs are a result of multiple factors that can
interact or co-exist, including genetic predisposition and
potential environmental triggers [43].
Observational studies never account for all possible
factors that lead to an outcome; there are always
unknown factors or unmeasurable known factors which
can be confounders. By comparison, in RCT the un-
known or unmeasurable factors are, by design, expected
to be consistently distributed in the treated and control
groups.
Our analysis was intentionally limited to assessing how
causal inference approaches can be applied to observa-
tional studies in the context of vaccines. We reached a
consensus to include three studies assessing different
objectives frequently addressed in vaccine clinical re-
search; (vaccine effectiveness, burden of disease and
safety) which we considered to provide acceptable diver-
sity in our examples. The objective was not an exhaust-
ive review of the various causal inference methods or of
recent developments in causal inference and analytical
methods such as Inverse probability weighting, G-
formula, G-estimation, Instrumental variable estimation,
and so on [54]. This will be the next step of our research
using both real data and simulations.
Our review was limited to three study designs. Never-
theless, our analysis can be used to guide observational
study design in the context of causal inference. Assess-
ment of potential causal effects using real data should start
by depicting the existing scientific knowledge about a
clearly defined research question. Exposure, outcome and
confounders need to be explicitly defined and causal dia-
grams developed to visualize the relationship between
these three major elements including the unmeasured
confounders. Conditional exchangeability could be
reached provided that the confounders are controlled
either by study design or by adjustment of the effect
estimate during the analysis. Standard methods to assess
causality in observational studies (for example, propensity
score-based methods, inverse probability of treatment
weighting, multivariable regression, etc.) require the as-
sumption of no unmeasured confounding. In our studies,
we did not consider possible unmeasured confounders but
these can occur in real-world data and therefore need to
be addressed. Methods have been developed to control for
them [55], but these require alternative assumptions for
identification (e.g., that certain measured variables are so-
called ‘instruments’). Interestingly, a recent revision of the
European Medicines Agency pharmacoepidemiology guid-
ance provides extensive recommendations to address con-
founding [56]. Finally, standard statistical software (for
example SAS or Stata) now include procedures for apply-
ing different causal inference methods, which prevent the
extrapolation bias to which standard regression methods
are prone [57].
Conclusion
In conclusion, the application of Hill’s criteria and coun-
terfactual reasoning in three observational studies showed
that definite causality could not be demonstrated. How-
ever, these approaches allowed us to determine the level
of certainty of causality, in each study and evaluating it
from very unlikely to very likely. The causal diagrams
appeared to be a complementary tool which can help in
designing observational studies and interpreting results of
analysis. Even if a causal effect could not be demonstrated
using only observational data, these studies have real value
in decision making in public health, being complementary
to RCTs which are not always feasible or ethical. More-
over, major scientific advances, such as Darwin’s develop-
ment of the theory of natural selection, were generated
entirely from observational data, highlighting the critical
contribution of such data to scientific thought.
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